#GRAIL #cancer detection #NHS-Galleri

GRAIL's NHS-Galleri Trial Results

The recent NHS-Galleri trial has emerged as a landmark study in cancer detection, showcasing an impressive reduction in Stage IV cancer diagnoses. During the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, GRAIL, Inc. revealed the extensive results of this trial aimed at improving early cancer detection methods.

The trial, conducted in collaboration with NHS England, involved over 142,000 participants ranging from ages 50 to 77 who were subjected to annual screenings with the Galleri blood test. This test targets more than 50 types of cancer, many of which have no existing screening method, and its purpose is to catch various cancers at an earlier stage, dramatically increasing the chances of successful treatment.

Key Findings

One of the most striking results was the reported decrease in Stage IV cancer diagnoses by 26% over three years in the third screening round. Notably, there was a 22% reduction in the second screening round as well. These findings are crucial because early-stage diagnoses can lead to more effective treatment options, greatly improving patient outcomes.

Despite the positive results, the trial observed no significant overall reduction in the combined primary endpoint of Stage III and IV cancers within the one-year follow-up period. However, the reduction in Stage IV cases is particularly significant, as it points to the study's success in shifting cancer diagnoses from late-stage to early-stage occurrences.

Impacts on Treatment

Dr. Josh Ofman, President and CEO-Elect at GRAIL, emphasized the trial's potential to change the cancer landscape, stating that the Galleri test enables earlier detection of cancers and allows healthcare providers to treat patients more proactively. The shift from metastatic presentations, where treatment options are limited, to earlier diagnoses profoundly affects the approach to patient care.

The trial highlighted that as much as 16% more cancers classified as Stage I-II were diagnosed, indicating that the Galleri test’s integration with standard screening practices could significantly alter the statistics surrounding cancer diagnoses. This capability is momentous for patients diagnosed with cancers that often present in advanced stages, such as ovarian and pancreatic cancers.

Anonymized Patient Testimonials

Participants like Nigel, 70, from Northeastern England, expressed relief upon being diagnosed with Stage I head and neck cancer thanks to the Galleri test.